+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Australia Microfluidics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • PDF Icon

    Report

  • 85 Pages
  • June 2025
  • Region: Australia
  • TechSci Research
  • ID: 5849417
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Australia Microfluidics Market was valued at USD 377.25 Million in 2024, and is expected to reach USD 505.58 Million by 2030, rising at a CAGR of 5.20%. Microfluidics, which involves the manipulation of tiny volumes of fluids within microscale channels, is gaining traction due to its ability to deliver rapid, accurate, and cost-efficient analyses.

In Australia, this market is advancing with the support of robust research infrastructure, increasing public and private investment, and rising demand for sophisticated diagnostic and therapeutic tools. The widespread application of lab-on-a-chip platforms in medical diagnostics is a major growth driver. However, the industry continues to face challenges such as high research and prototyping costs, complex regulatory pathways, and the need for specialized manufacturing capabilities. Additionally, the technical difficulty of ensuring consistent performance and scalability for commercial-scale production remains a significant barrier to wider market adoption.

Key Market Drivers

Growth in Healthcare Industry

Australia's dual public-private healthcare model, largely funded through Medicare, plays a central role in supporting the adoption of innovative technologies like microfluidics. The country's healthcare landscape is evolving with a strong emphasis on early diagnosis, personalized treatment, and technological advancement. This progression is significantly boosting demand for high-precision and cost-effective diagnostic tools. Microfluidic devices, known for their rapid fluid processing capabilities, are increasingly integrated into Australian clinical practices to meet these evolving healthcare needs. Their compact design, minimal sample requirements, and efficiency make them ideal for point-of-care applications, contributing to the market’s expansion within the country’s health sector.

Key Market Challenges

High Cost of Manufacturing

The high cost of manufacturing remains a critical barrier in the Australia microfluidics market, particularly in the shift from academic research to full-scale commercialization. Although Australia has demonstrated strong capabilities in microfluidics research, the complexity and cost of production hinder the widespread deployment of these technologies. Manufacturing microfluidic devices often requires cleanroom environments, high-precision machinery, and the use of specialized materials like silicon, polymers, or glass. Techniques such as injection moulding and soft lithography further add to the cost due to the need for skilled personnel and stringent quality control. These factors collectively contribute to elevated production costs, limiting the scalability and commercial viability of microfluidic innovations in Australia.

Key Market Trends

Growing Emphasis on Point-of-Care (PoC) Diagnostics

There is a growing emphasis on point-of-care (PoC) diagnostics within the Australia microfluidics market. Increasingly, the healthcare sector is focusing on delivering quick, accessible, and patient-centric diagnostic solutions - particularly in rural or under-resourced regions. Microfluidic technologies, known for their precision and low-volume sample requirements, are ideally suited for these applications. Concurrently, regulatory authorities in Australia are under pressure to ease the rebate and compliance landscape for PoC testing, enabling broader usage among general practitioners and frontline healthcare providers. This regulatory shift, combined with rising clinical demand, is accelerating the integration of microfluidic platforms into PoC diagnostics across the country.

Key Market Players

  • MTPConnect
  • SCHOTT AG
  • Microfluidics Biomedical Pty. Ltd.
  • SDR Scientific Pty Ltd
  • WHITE RABBIT SCIENTIFIC LIMITED
  • Australian National Fabrication Facility
  • Merck Pty. Ltd.

Report Scope

In this report, the Australia Microfluidics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Australia Microfluidics Market, By Material:

  • Glass
  • Silicon
  • Polymers
  • Others

Australia Microfluidics Market, By Application:

  • In-vitro Diagnostics
  • Pharmaceutical & Life Science Research & Manufacturing
  • Therapeutics
  • Others

Australia Microfluidics Market, By Region:

  • New South Wales
  • Victoria
  • Queensland
  • Western Australia
  • South Australia
  • Tasmania
  • Northern Territory

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Australia Microfluidics Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Australia Microfluidics Market
5. Australia Microfluidics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Material (Glass, Silicon, Polymers, Others)
5.2.2. By Application (In-vitro Diagnostics, Pharmaceutical & Life Science Research & Manufacturing, Therapeutics, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. New South Wales Microfluidics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Material
6.2.2. By Application
7. Victoria Microfluidics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Material
7.2.2. By Application
8. Queensland Microfluidics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Material
8.2.2. By Application
9. Western Australia Microfluidics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Material
9.2.2. By Application
10. South Australia Microfluidics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Material
10.2.2. By Application
11. Tasmania Microfluidics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Material
11.2.2. By Application
12. Northern Territory Microfluidics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Material
12.2.2. By Application
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
14.1. Merger & Acquisition (If Any)
14.2. Product Launches (If Any)
14.3. Recent Developments
15. Disruptions : Conflicts, Pandemics and Trade Barriers16. Australia Microfluidics Market: SWOT Analysis
17. Porters Five Forces Analysis
17.1. Competition in the Industry
17.2. Potential of New Entrants
17.3. Power of Suppliers
17.4. Power of Customers
17.5. Threat of Substitute Products
18. Competitive Landscape
18.1. MTPConnect
18.1.1. Business Overview
18.1.2. Company Snapshot
18.1.3. Products & Services
18.1.4. Financials (As Reported)
18.1.5. Recent Developments
18.1.6. Key Personnel Details
18.1.7. SWOT Analysis
18.2. SCHOTT AG
18.3. Microfluidics Biomedical Pty. Ltd.
18.4. SDR Scientific Pty Ltd
18.5. WHITE RABBIT SCIENTIFIC LIMITED
18.6. Australian National Fabrication Facility
18.7. Merck Pty. Ltd.
19. Strategic Recommendations20. About the Publisher & Disclaimer

Companies Mentioned

  • MTPConnect
  • SCHOTT AG
  • Microfluidics Biomedical Pty. Ltd.
  • SDR Scientific Pty Ltd
  • WHITE RABBIT SCIENTIFIC LIMITED
  • Australian National Fabrication Facility
  • Merck Pty. Ltd.

Table Information